LTC2579894I2 - CGRP antikūnai - Google Patents

CGRP antikūnai

Info

Publication number
LTC2579894I2
LTC2579894I2 LTPA2019011C LTPA2019011C LTC2579894I2 LT C2579894 I2 LTC2579894 I2 LT C2579894I2 LT PA2019011 C LTPA2019011 C LT PA2019011C LT PA2019011 C LTPA2019011 C LT PA2019011C LT C2579894 I2 LTC2579894 I2 LT C2579894I2
Authority
LT
Lithuania
Prior art keywords
cgrp antibodies
cgrp
antibodies
Prior art date
Application number
LTPA2019011C
Other languages
English (en)
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of LTPA2019011I1 publication Critical patent/LTPA2019011I1/lt
Publication of LTC2579894I2 publication Critical patent/LTC2579894I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTPA2019011C 2010-06-10 2019-04-12 CGRP antikūnai LTC2579894I2 (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35332310P 2010-06-10 2010-06-10
PCT/US2011/039381 WO2011156324A1 (en) 2010-06-10 2011-06-07 Cgrp antibodies

Publications (2)

Publication Number Publication Date
LTPA2019011I1 LTPA2019011I1 (lt) 2019-05-10
LTC2579894I2 true LTC2579894I2 (lt) 2020-03-25

Family

ID=45096388

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP11792989.3T LT2579894T (lt) 2010-06-10 2011-06-07 Cgrp antikūnai
LTPA2019011C LTC2579894I2 (lt) 2010-06-10 2019-04-12 CGRP antikūnai

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP11792989.3T LT2579894T (lt) 2010-06-10 2011-06-07 Cgrp antikūnai

Country Status (33)

Country Link
US (3) US9073991B2 (lt)
EP (2) EP3318272B1 (lt)
JP (2) JP6021806B2 (lt)
KR (1) KR101489566B1 (lt)
CN (2) CN104292332B (lt)
AR (1) AR081434A1 (lt)
AU (1) AU2011265050B2 (lt)
BR (1) BR112012031501B1 (lt)
CA (1) CA2802102C (lt)
CY (2) CY1119789T1 (lt)
DK (1) DK2579894T3 (lt)
EA (1) EA022931B1 (lt)
ES (2) ES2930321T3 (lt)
HR (1) HRP20171992T1 (lt)
HU (2) HUE038135T2 (lt)
IL (2) IL222885B (lt)
JO (1) JO3330B1 (lt)
LT (2) LT2579894T (lt)
LU (1) LUC00112I2 (lt)
ME (1) ME02862B (lt)
MX (2) MX363209B (lt)
NL (1) NL300979I2 (lt)
NO (2) NO2579894T3 (lt)
NZ (1) NZ603607A (lt)
PL (1) PL2579894T3 (lt)
PT (1) PT2579894T (lt)
RS (1) RS56638B1 (lt)
SG (1) SG185648A1 (lt)
SI (1) SI2579894T1 (lt)
TW (1) TWI423818B (lt)
UA (1) UA109658C2 (lt)
WO (1) WO2011156324A1 (lt)
ZA (1) ZA201208996B (lt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5123197B2 (ja) 2005-11-14 2013-01-16 ライナット ニューロサイエンス コーポレイション カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体およびその使用方法
JP5537441B2 (ja) 2008-03-04 2014-07-02 ファイザー・リミテッド 慢性疼痛を治療する方法
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
NZ732970A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
EP3662932B1 (en) * 2011-05-20 2021-04-07 H. Lundbeck A/S Anti-cgrp compositions and use thereof
CN103957935B (zh) 2011-05-20 2018-04-03 奥尔德生物控股有限责任公司 抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
HRP20240159T1 (hr) 2014-03-21 2024-04-12 Teva Pharmaceuticals International Gmbh Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
US10556945B2 (en) * 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CN107108715A (zh) 2014-10-24 2017-08-29 默沙东公司 胰高血糖素和glp‑1受体的共激动剂
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
TWI799849B (zh) 2015-04-24 2023-04-21 美商安美基公司 治療或預防偏頭痛之方法
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
JP6592600B2 (ja) * 2015-10-30 2019-10-16 イーライ リリー アンド カンパニー 抗ｃｇｒｐ／抗ｉｌ−２３二重特異性抗体及びその使用
CN105483091A (zh) * 2015-12-29 2016-04-13 天津三箭生物技术股份有限公司 小鼠抗人Calcitonin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
AU2017211043A1 (en) * 2016-01-28 2018-06-14 Eli Lilly And Company CGRP antibodies and uses thereof
EP3411066A1 (en) 2016-02-01 2018-12-12 Eli Lilly and Company Parathyroid hormone anti-rankl antibody fusion compounds
MX2018016330A (es) 2016-06-27 2020-02-17 Univ California Combinaciones para tratamiento del cáncer.
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
MX2019003338A (es) 2016-09-23 2019-09-26 Teva Pharmaceuticals Int Gmbh Tratamiento de cefalea en racimos.
WO2018160897A1 (en) * 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center, Inc. Preventing post-ictal headaches
TW201902926A (zh) 2017-05-03 2019-01-16 美商美國禮來大藥廠 抗cgrp／抗il-23雙特異性抗體及其用途
WO2018237159A1 (en) * 2017-06-21 2018-12-27 Cephalon, Inc. Cation exchange chromatography wash buffer
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
US10738110B2 (en) 2018-01-12 2020-08-11 Amgen Inc. PAC1 antibodies and uses thereof
WO2019231800A1 (en) 2018-05-31 2019-12-05 Eli Lilly And Company Anti-cgrp antibodies for treating menstrual-related migraines
WO2020041468A1 (en) 2018-08-22 2020-02-27 Eli Lilly And Company Anti-cgrp antibodies for treatment-resistant patients
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
EP3744400A1 (en) * 2019-05-28 2020-12-02 Etablissement Français du Sang Car-t cells targeting il-1rap and their use in acute myeloid leukemia (aml)
WO2020239014A1 (zh) * 2019-05-30 2020-12-03 山东博安生物技术有限公司 抗cgrp抗体及其应用
CN114555792A (zh) 2019-10-15 2022-05-27 伊莱利利公司 重组改造的、脂肪酶/酯酶缺陷型哺乳动物细胞系
CA3077973A1 (en) 2020-04-06 2021-10-06 H. Lundbeck A/S Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
US20250186580A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
EP4570913A1 (en) * 2022-08-11 2025-06-18 Shanghai Junshi Biosciences Co., Ltd. Anti-cgrp antibody and use
CN118271438B (zh) * 2024-05-27 2024-08-30 上海宏成药业有限公司 抗cgrp抗体或其抗原结合片段及其用途
CN119320450B (zh) * 2024-12-13 2025-07-25 中国人民解放军军事科学院军事医学研究院 针对降钙素基因相关肽的抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2134212T3 (es) * 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
EP0940468A1 (en) * 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO2005035753A1 (ja) * 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
WO2006110214A2 (en) * 2005-04-08 2006-10-19 Medimmune, Inc. Antibodies against mammalian metapneumovirus
JP5123197B2 (ja) * 2005-11-14 2013-01-16 ライナット ニューロサイエンス コーポレイション カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体およびその使用方法
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
JP5537441B2 (ja) * 2008-03-04 2014-07-02 ファイザー・リミテッド 慢性疼痛を治療する方法
DK2265288T3 (en) 2008-03-04 2016-06-06 Labrys Biologics Inc Methods for the treatment of inflammatory pain
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo

Also Published As

Publication number Publication date
CA2802102C (en) 2016-07-26
IL242409B (en) 2020-07-30
HRP20171992T1 (hr) 2018-02-09
JP6466883B2 (ja) 2019-02-06
CY2019017I2 (el) 2020-05-29
EP3318272A1 (en) 2018-05-09
US9505838B2 (en) 2016-11-29
CN104292332B (zh) 2019-11-01
CY1119789T1 (el) 2018-06-27
NZ603607A (en) 2014-09-26
PT2579894T (pt) 2018-02-06
BR112012031501B1 (pt) 2020-02-11
CY2019017I1 (el) 2020-05-29
SG185648A1 (en) 2012-12-28
MX2012014480A (es) 2013-02-07
LUC00112I2 (lt) 2019-12-27
CA2802102A1 (en) 2011-12-15
UA109658C2 (xx) 2015-09-25
US20110305711A1 (en) 2011-12-15
AU2011265050B2 (en) 2013-06-27
MX340999B (es) 2016-08-03
US20150259415A1 (en) 2015-09-17
HUE038135T2 (hu) 2018-09-28
IL222885B (en) 2019-09-26
SI2579894T1 (en) 2018-01-31
US9073991B2 (en) 2015-07-07
KR101489566B1 (ko) 2015-02-03
EP2579894A1 (en) 2013-04-17
ES2930321T3 (es) 2022-12-09
NO2579894T3 (lt) 2018-04-21
HUS1900020I1 (hu) 2019-05-28
MX363209B (es) 2019-03-14
KR20130034024A (ko) 2013-04-04
EP2579894B1 (en) 2017-11-22
AU2011265050A1 (en) 2012-11-08
EA201270769A1 (ru) 2013-04-30
DK2579894T3 (en) 2018-01-15
IL222885A0 (en) 2012-12-31
NL300979I2 (nl) 2019-07-11
NL300979I1 (nl) 2019-04-17
TWI423818B (zh) 2014-01-21
NO2019017I1 (no) 2019-04-05
JP2013532143A (ja) 2013-08-15
LTPA2019011I1 (lt) 2019-05-10
PL2579894T3 (pl) 2018-04-30
EP2579894A4 (en) 2013-12-04
ZA201208996B (en) 2014-05-28
CN104292332A (zh) 2015-01-21
ME02862B (me) 2018-04-20
EA022931B1 (ru) 2016-03-31
RS56638B1 (sr) 2018-03-30
LT2579894T (lt) 2018-02-26
JP2017014203A (ja) 2017-01-19
HK1203211A1 (en) 2015-10-23
LUC00112I1 (lt) 2019-04-10
JO3330B1 (ar) 2019-03-13
BR112012031501A2 (pt) 2016-10-25
TW201210618A (en) 2012-03-16
US20170073403A1 (en) 2017-03-16
JP6021806B2 (ja) 2016-11-09
EP3318272B1 (en) 2022-08-10
WO2011156324A1 (en) 2011-12-15
ES2656000T3 (es) 2018-02-22
CN102946905B (zh) 2014-10-15
CN102946905A (zh) 2013-02-27
AR081434A1 (es) 2012-08-29

Similar Documents

Publication Publication Date Title
LTC2579894I2 (lt) CGRP antikūnai
HUS2300021I1 (hu) Anti-IL-36R antitestek
BR112012030311A2 (pt) anticorpo
HUE038962T2 (hu) DLL3-ellenes antitest
IL222272B (en) Anti-erbb3 antibodies
DK2521736T3 (da) Humaniserede antistoffer
EP2629796A4 (en) ANTIBODY
CO6811812A2 (es) Anticuerpo anti-b7-h3
BR112013010688A2 (pt) anticorpos anti c-met
LT3284754T (lt) Antikūnai prieš cd38
PT2406284T (pt) Anticorpos anti-bcma
CO6791565A2 (es) Anticuerpos anti-notch1
CR20140127A (es) Anticuerpo anti-abtcr
DK3741883T5 (da) Antistofbiblioteker
DK3178851T3 (da) Anti-cd40-antistoffer
EP2473531A4 (en) Anti-gitr antibodies
CR20130228A (es) Anticuerpos neutralizadores anti-ccl20
PL3088421T3 (pl) Przeciwciała monoklonalne do zastosowania w diagnostyce i leczeniu nowotworów i choroby autoimmunologicznej
DK3202789T3 (da) Anti-vla-4-antistoffer
DE112011101333A5 (de) Parkouraufbau
EP2578316A4 (en) PIPETTE
CO6841994A2 (es) Anticuerpos